View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 7, 2018

Deals this week: Boehringer Ingelheim, UCB, Janssen Pharmaceutical

Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.

Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.

Both the companies have agreed to develop new drugs for the treatment of central nervous system (CNS) diseases by focusing on orphan G protein-coupled receptors (GPCRs).

The collaboration will combine Boehringer’s discovery and clinical development expertise and Domain’s DTect-All and bioSens-All platforms to develop new GPCR-targeted drugs for neuropsychiatric disorders.

Based in Germany, Boehringer Ingelheim is a research-driven pharmaceutical company, while Domain Therapeutics is a Canadian biopharmaceutical company.

Belgian biopharmaceutical company UCB has agreed to invest £1bn ($1.27bn) to support a purpose-built facility and research and development activities aimed to accelerate early detection of deadly diseases.

The collaboration will use artificial intelligence (AI) to develop early disease detection technology and new treatments.

The UK Government is supporting the project by providing £79m ($100.55m). The deal also includes a £50m ($63.6m) investment by Roche and a total of £80m ($101.8m) in funding from five cell and gene therapy companies.

Other companies involved in the partnership are IQVIA, Genomics England, Autolus, Oxford BioMedica, Cobra Biologics, Roslin CT, and Bellicum.

“The collaboration will use artificial intelligence (AI) to develop early disease detection technology and new treatments.”

Janssen Pharmaceutical affiliate Cilag International has entered a deal with argenx to collaborate on the development and global commercialisation of cancer immunotherapy cusatuzumab (ARGX-110).

argenx will receive an upfront payment of $300m from Janssen and be eligible to receive up to $1.3bn upon achieving development, regulatory and sales milestones.

Cusatuzumab is intended for the treatment of acute myeloid leukaemia (AML), high-risk myelodysplastic syndromes (MDS), next-generation CD70 antibodies, and other future indications.

The deal provides argenx with an option to participate in commercialisation efforts in the US and share royalties equally with its partner. argenx will, however, receive double-digit sales royalties outside the country.

Based in Belgium, Cilag International manufactures and distributes pharmaceutical products, while Dutch company argenx develops innovative antibody therapeutics for cancer and autoimmune diseases.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology